Skip to main navigation Skip to search Skip to main content

Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract

  • European Atherosclerosis Society Consensus Panel
  • University of Geneva
  • Imperial College London
  • University of Gothenburg
  • Sahlgrenska University Hospital
  • University of Milan
  • Sorbonne Université
  • Ghent University
  • Western University
  • Amsterdam University Medical Center
  • Emory University
  • BACPAC Resources
  • Leipzig University
  • University of Toronto
  • Heidelberg University 
  • Medical University of Graz
  • University of Copenhagen
  • University of the Witwatersrand
  • German Diabetes Center Düsseldorf
  • Heinrich Heine University Düsseldorf
  • Hospital Israelita Albert Einstein
  • Universidade de São Paulo
  • Metabolic and Atherosclerosis Research Center
  • Institute of Living
  • Hacettepe University
  • European Atherosclerosis Society
  • Columbia University
  • Institut national de la santé et de la recherche médicale

Research output: Contribution to journal › Article › peer-review

341 Scopus citations

Abstract

Aims: To objectively appraise evidence for possible adverse effects of long-term statin therapy on glucose homeostasis, cognitive, renal and hepatic function, and risk for haemorrhagic stroke or cataract. Methods and results: A literature search covering 2000-2017 was performed. The Panel critically appraised the data and agreed by consensus on the categorization of reported adverse effects. Randomized controlled trials (RCTs) and genetic studies show that statin therapy is associated with a modest increase in the risk of new-onset diabetes mellitus (about one per thousand patient-years), generally defined by laboratory findings (glycated haemoglobin ≥6.5); this risk is significantly higher in the metabolic syndrome or prediabetes. Statin treatment does not adversely affect cognitive function, even at very low levels of low-density lipoprotein cholesterol and is not associated with clinically significant deterioration of renal function, or development of cataract. Transient increases in liver enzymes occur in 0.5-2% of patients taking statins but are not clinically relevant; idiosyncratic liver injury due to statins is very rare and causality difficult to prove. The evidence base does not support an increased risk of haemorrhagic stroke in individuals without cerebrovascular disease; a small increase in risk was suggested by the Stroke Prevention by Aggressive Reduction of Cholesterol Levels study in subjects with prior stroke but has not been confirmed in the substantive evidence base of RCTs, cohort studies and case-control studies. Conclusion: Long-term statin treatment is remarkably safe with a low risk of clinically relevant adverse effects as defined above; statin-associated muscle symptoms were discussed in a previous Consensus Statement. Importantly, the established cardiovascular benefits of statin therapy far outweigh the risk of adverse effects.

Original languageEnglish
Pages (from-to)2526-2539
Number of pages14
JournalEuropean Heart Journal
Volume39
Issue number27
DOIs
StatePublished - Jul 14 2018

Fingerprint

Dive into the research topics of 'Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract'. Together they form a unique fingerprint.

Cite this